Novartis Corporation’s Myfortic Poses Fetal Risks Says FDA

LOS ANGELES, Nov 27 (Reuters) - The U.S. Food and Drug Administration said on Tuesday that Novartis AG's (NOVN.VX: Quote, Profile, Research) organ rejection drug, Myfortic, increases risk of first-trimester miscarriage and birth defects.